We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Idmos | IDO | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 3.00 | 01:00:00 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 3.00 |
| Top Posts |
|---|
Posted at 19/5/2008 14:26 by seanmiller lol, would you believe it!!!.A colleague of mine had a few of these and he just said the company is in talks with a potential buyer. The administrators are not releasing details (Ernst Young), as you would expect but apparently it is close to a decision. They think it may be as close as a couple of weeks, but don't hold him to it (just repeating what he was told). Ernst & Young said they are not allowed to give any details and the outcome may be one of many, but they are definately talking to a prospective buyer. theman4 does not deserve that lifeline lol, but other unfortunate investors do. anyways, good luck to the holders. I'll keep my eye out ;) I |
Posted at 02/5/2008 14:14 by seanmiller which space? the one between your ears?no bid, company bust, no return to investors, nothing, nada, zilch lol watch that space!!! |
Posted at 15/7/2007 15:47 by jonwig Lifting the lid a bit here, but still a lot unanswered:Sacked Idmos chief 'ran out of knowledge' DOUGLAS FRIEDLI STEPHEN Westwood, the ousted chief executive of dental technology company Idmos, was removed because he "ran out of technical knowledge", chairman John Pool has claimed. Westwood was sacked last week amid claims that investors were furious about a two-thirds decline in the company's share price and delays to the launch of its lead product. But Pool, who has ordered a review of Idmos's operations, said Westwood left because he had taken the company as far as he could go: "He just ran out of technical knowledge. He got out of his technical background. He was starting to feel uncomfortable with where he was. "Anyone who has been in life sciences knows there are phases of a company where you have an input, and then you need a different input, and we were getting to the phase where we needed a different input." Westwood did not return calls from Scotland on Sunday. Westwood's job is likely to be taken by Graham Lay, the company's operations director who is expected to become chief operating officer this week. Pool said: "Graham Lay is a guy who we have looked for for some considerable length of time. He is far more aggressive than Stephen was. You can be aggressive if you have the technical knowledge. He is probably the strongest candidate for chief executive. I have no doubt about that." Scotland on Sunday last week revealed that Lay had been appointed operations director, and subsequent events have turned the spotlight on the former Johnson & Johnson executive. Pool said he had ordered a review of the Dundee company's business to cut costs and speed up the development of a new range of medical devices which use its sound wave technology in bones and other tissue. Among the measures being considered are a reduction in pay for some directors and more efficient manufacturing processes at its suppliers. He added that Idmos had considered moving manufacturing to Dentsply, the US group which is expected to distribute its products. Idmos's main product is a sound wave probe which can detect the onset of tooth decay. The same technology could be used to detect osteoporosis, and Pool said he hoped to have such a device on the market by the middle of next year. He said: "Even if we get 100% of the dentists' sales, it will still be less than the potential on the medical side." Pool last week switched from a non-executive to an executive role to guide Idmos through his proposed changes. He said he was disappointed by Idmos's share price, which collapsed this year when the company raised money to get its first products to market: "I don't think it represents the potential there is in the company. It is the way of the Alternative Investment Market at the moment; I am involved with another company which has £30m worth of contracts yet its value is just £17m." Pool said Westwood had been "a gentleman" in agreeing to help in the handover of the company to Lay and the board, including chief clinical officer Nigel Pitts, technology director Chris Longbottom and corporate development director Francis Madden. Idmos was set up to commercialise dental technology developed at St Andrews and Dundee universities. Westwood joined in 2004 and helped to steer the company through a flotation that year which raised £5m and a further £2m this year. |
Posted at 12/7/2007 09:11 by jonwig Quite so, kardiff.Yet the departure of Westwood will, if I read it right, result in an extra executive director!! This looks like an excellent idea badly managed throughout. AMBER ... you wrote: "Having watched Dentsply's investor presentation I felt some reassurance that they are committed to launch of the products." Is this something we can find online? Have you a link, please? |
Posted at 12/7/2007 08:44 by kardiff In late 2005 inherited a number of these shares from a professor of prosthetic dentistry and have grown increasingly concerned at their performance. Reading between the lines of the last announcement, it does appear that Westwood has driven the company rather badly, and clearly he had to go.I was also disappointed that at the time of the last fundraising that no information was made available to existing shareholders. Clearly the new investors would have made fully aware of the progress with the business plan but not even a summary was issued at that time. The other announcements have been lacking in clarity, in my opinion - what was the real reason to try and develop a new product line, for example. All in all it appears a classic story of a company trying to run before being able walk and moreover having extremely poor investor relations. Credibility is now an issue and I am not confident that they will be able to make progress with the product development without further dilution. |
Posted at 09/7/2007 18:26 by amberandorange jonwigTo confirm I am none of the above. I am a shareholder and have been very disappointed in recent events. I have to say that I was concerned about the cost of the corporate brochure, it seemed somewhat excessive given the early stage of the company's development. It is also unclear to me why it has taken so long for the company to gain 510K approval , it is not a "marketing certificate" it is a pre-market notification document which is issued by CDRH. The launch of a novel product based on a new technology requires a substantial level of evidence based data if it is not be damaged by competitors. Again , however this is self evident and should not have been a surprise. Like you I was very concerned to see a broadening of the company's commercial horizons. If they plan to follow an out-licensing strategy they must have a proven commercial model to gain significant return to share holders, otherwise the company's technology will be discounted . They need to focus,focus and focus until the revenue stream is up and running.Having watched Dentsply's investor presentation I felt some reassurance that they are committed to launch of the products. I would like to see the Board strengthened with medical device commercialization expertise, preferably with a US background. Interfacing with the City is critical but the company must now deliver and there is no substitute for hands on experience and in market expertise |
Posted at 25/2/2006 11:02 by jonwig IC this week:Idmos raised nearly £4m when it joined Aim via a placing at 135p in November 2004. It topped that up with £2.3m via another placing at 158p last autumn. But, after peaking then at over 200p, the shares have since fallen back as investors wait for the company's technology to be commercialised. Idmos certainly has an interesting product that uses a range of frequencies to pass low levels of electrical current through teeth to identify decay. This provides greater accuracy than x-rays without the associated safety risks. It also has a global distribution agreement with Dentsply. Future uses may include lesion detection and cancer imaging. Broker Code forecasts 2006-07 sales of £4.8m and break-even. Good value. And Shares Mag, No58 in the 'top 100 prospects': 58 IDMOS The company's tooth decay detection technology could mean an end to fillings and should see an uptake in sales now a deal has been signed with US major Dentsply International. Yesterday's 2,000 buy was my top-up. |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
